Should manipulation of myocardial substrate utilization patterns be a component of the congestive heart failure therapeutic paradigm?
From
A H
AH
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D005227:Fatty Acids / Q000378:metabolism*; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use; D009206:Myocardium / Q000378:metabolism*; D010101:Oxygen Consumption
D000319:Adrenergic beta-Antagonists; D005227:Fatty Acids; D008790:Metoprolol